Analysis of 4-1BB Ligand (4-1BBL)-Deficient Mice and of Mice Lacking Both 4-1BBL and CD28 Reveals a Role for 4-1BBL in Skin Allograft Rejection and in the Cytotoxic T Cell Response to Influenza Virus
Author:
Affiliation:
1. *Department of Immunology, University of Toronto, Toronto, Ontario, Canada;
2. †Department of Medical Biophysics, University of Toronto and the Ontario Cancer Institute, Toronto, Ontario, Canada; and
3. ‡Immunex, Seattle, WA 98101-2936
Abstract
Publisher
The American Association of Immunologists
Subject
Immunology,Immunology and Allergy
Link
https://journals.aai.org/jimmunol/article-pdf/163/9/4833/1495596/im219904833p.pdf
Reference42 articles.
1. Lenschow, D. J., T. L. Walunas, J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14: 233
2. Shahinian, A., K. Pfeffer, K. P. Lee, T. M. Kundig, K. Kishihara, A. Wakeham, K. Kawai, P. S. Ohashi, C. B. Thompson, T. W. Mak. 1993. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261: 609
3. Kawai, K., A. Shahinian, T. W. Mak, P. S. Ohashi. 1996. Skin allograft rejection in CD28-deficient mice. Transplantation 61: 352
4. Gause, W. C., S. J. Chen, R. J. Greenwald, M. J. Halvorson, P. Lu, X. D. Zhou, S. C. Morris, K. P. Lee, C. H. June, F. D. Finkelman, J. F. Urban, R. Abe. 1997. CD28 dependence of T cell differentiation to IL-4 production varies with the particular type 2 immune response. J. Immunol. 158: 4082
5. Wen, T., K. Kono, A. Shahinian, R. Kiessling, T. W. Mak, G. Klein. 1997. CD28 is not required for rejection of unmanipulated syngeneic and autologous tumors. Eur. J. Immunol. 27: 1988
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. 4-1BB immunotherapy: advances and hurdles;Experimental & Molecular Medicine;2024-01-04
2. Circulating CD137+ T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients;International Journal of Molecular Sciences;2023-04-12
3. CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary;Cancer Discovery;2022-12-28
4. The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes;Frontiers in Immunology;2022-07-22
5. Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking;Frontiers in Pharmacology;2022-07-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3